Phd
Financiado
Deciphering PI3K biology in health and disease
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of...
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of human cancers. Therefore, PI3Ks have emerged as important targets for drug discovery and, during 2014, the first PI3K inhibitor was approved by FDA in the US for the treatment of a lymphocytic leukaemia. Nonetheless, our understanding of PI3K-mediated signalling is still poor and only a fraction of the potential therapeutic applications have been addressed so far, leaving a large amount of translational work unexplored. Europe features a set of top quality research institutions and pharmaceutical companies focused on PI3K studies but their activities have been so far scattered. This proposal fills this gap by providing a multidisciplinary network (biochemistry, mouse studies, disease models, drug development, software development) and an unprecedented training opportunity from the bench to the bedside (from pre-clinical discoveries to clinical trials), through cutting edge molecular biology, drug discovery and clinical trial organization. The proposal is aimed at training young investigators in deep understanding of the different PI3K isoforms in distinct tissues and to translate this knowledge into a new generation of PI3K inhibitors, treatment modalities and into identify new uses for existing PI3K inhibitors.
ver más
Duración del proyecto: 50 meses
Fecha Inicio: 2015-08-07
Fecha Fin: 2019-10-31
Fecha Fin: 2019-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-ITN-2015-ETN:
Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN)
Cerrada
hace 9 años
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
FUNDACIO INSTITUT D?INVESTIGACIO BIOMEDICA DE...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
16M
Perfil tecnológico
TRL
4-5
16M
498.43K€ |
Participante